Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ROIV · as of Sep 30, 2024
Ownership Breakdown
311
Institutional Holders
▲ 4 vs Q2
$6.57B
Total Inst. Value
▲ $796.45M vs Q2
719.27M
Shares Outstanding
freeFloat 71.77%
569.14M
13F Shares Held
▲ 23.14M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ROIV largest shareholders · institutional ownership
Q3 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SB INVESTMENT ADVISERS (UK) LTD pharmaceutical preparations | 65.93M | 8.96% | 8.96% | $760.88B | Nov 14, 2024 | ▼ 5.43M |
QVT FINANCIAL LP pharmaceutical preparations | 65.79M | 8.95% | 8.95% | $759.26B | Nov 14, 2024 | ▼ 926.0K |
VIKING GLOBAL INVESTORS LP pharmaceutical preparations | 54.10M | 7.36% | 7.36% | $624.30B | Nov 14, 2024 | ▼ 15.06M |
FMR LLC pharmaceutical preparations | 49.15M | 6.68% | 6.68% | $567.13B | Nov 13, 2024 | ▲ 2.59M |
BLACKROCK, INC. pharmaceutical preparations | 41.96M | 5.71% | 5.71% | $484.24B | Nov 13, 2024 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 41.68M | 5.67% | 5.67% | $481.02B | Nov 13, 2024 | ▲ 33.49M |
MORGAN STANLEY pharmaceutical preparations | 29.67M | 4.03% | 4.03% | $342.44B | May 14, 2025 | ▲ 343.9K |
RUBRIC CAPITAL MANAGEMENT LP pharmaceutical preparations | 22.40M | 3.05% | 3.05% | $258.50B | Nov 13, 2024 | ▼ 600.0K |
STATE STREET CORP pharmaceutical preparations | 19.56M | 2.66% | 2.66% | $225.74B | Nov 14, 2024 | ▲ 1.12M |
PATIENT SQUARE CAPITAL LP pharmaceutical preparations | 12.23M | 1.66% | 1.66% | $141.12B | Nov 14, 2024 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2024 vs prior quarter
Q3 2024
28
Increased
+55.65M shares3
New Positions
first time holders13
Decreased
−26.28M shares0
Sold Out
fully exitedNet shares change (top 50)
+29.37M
+55.65M / −26.28M
Net new holders
+18
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ROIV insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
9
Buy transactions
10
Sell transactions
0.90
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Venker Eric President & Immunovant CEO | May 20, 2026 | Tax Withhold | 34,483 | $32.41 | $1.12M | 1.61M | Form 4 ↗ |
Venker Eric President & Immunovant CEO | May 22, 2026 | Sale | 200,000 | $30.27 | $6.05M | 1.61M | Form 4 ↗ |
Pulik Richard CFO | May 20, 2026 | Tax Withhold | 18,962 | $32.41 | $614.6K | 278.5K | Form 4 ↗ |
Venker Eric President & Immunovant CEO | Apr 20, 2026 | Sale | 200,000 | $29.59 | $5.92M | 1.65M | Form 4 ↗ |
Pulik Richard CFO | Apr 20, 2026 | Award | 60,644 | — | — | 297.5K | Form 4 ↗ |
Pulik Richard CFO | Apr 20, 2026 | Award | 84,026 | $29.08 | $2.44M | 84.0K | Form 4 ↗ |
Humes Jennifer Chief Accounting Officer | Apr 20, 2026 | Award | 29,173 | — | — | 113.4K | Form 4 ↗ |
Humes Jennifer Chief Accounting Officer | Apr 20, 2026 | Award | 27,157 | $29.08 | $789.7K | 27.2K | Form 4 ↗ |
Oren Ilan director | Apr 17, 2026 | Award | 896 | — | — | 120.3K | Form 4 ↗ |
Oren Ilan director | Apr 17, 2026 | Tax Withhold | 95 | $29.83 | $2.8K | 120.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Roivant Sciences Ltd. (ROIV) is primarily owned by institutional investors, who hold approximately 79.1% of total shares outstanding. Company insiders own approximately 28.23%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Roivant Sciences Ltd. is SB INVESTMENT ADVISERS (UK) LTD, holding approximately 65.93 million shares — equal to 8.96% of outstanding shares — as of September 30, 2024.
A total of 311 institutional investors currently hold ROIV stock, with a combined institutional value of approximately $6.57 billion as of the most recent 13F filing period.
Frequently asked questions
ROIV ownershipRoivant Sciences Ltd. (ROIV) is primarily owned by institutional investors, who hold approximately 79.1% of shares. The largest shareholder is SB INVESTMENT ADVISERS (UK) LTD with a 8.96% stake. Company insiders hold 28.23%. Data sourced from SEC Form 13F as of September 30, 2024.